Opendata, web and dolomites

HEARTguide SIGNED

Disruptive personalized pre-operative planning tool for transcatheter procedures

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "HEARTguide" data sheet

The following table provides information about the project.

Coordinator
FEOPS NV 

Organization address
address: TECHNOLOGIEPARK ZWIJNAARDE 122
city: GENT
postcode: 9052
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 4˙682˙512 €
 EC max contribution 3˙214˙583 € (69%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-SMEInst-2018-2020-3
 Funding Scheme SME-2b
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FEOPS NV BE (GENT) coordinator 3˙214˙583.00

Map

 Project objective

While transcatheter procedures for heart structural diseases present strong advantages over open-heart surgeries, their adoption remains low. Indeed, the difficulties to predict the optimal size and positioning of the heart implant cause high rate of complication. FEops has developed HEARTguide, a cloud-based pre-operative planning tool that will enhance the use of the transcatheter procedures. HEARTguide simulates virtually the interactions between the implant and the real patient anatomy. HEARTguide predictive power was shown in a retrospective clinical trial on 80 patient cases. HEARTguide is CE marked for two indications. The next generation of HEARTguide will be artificial intelligence-powered and the analysis will be automated. The enhanced platform will be clinically validated through four clinical trials including 700 patients and limited access releases with selected physicians. The data base contains 1000 patient data that surpasses all over tools marketed. Agreements have been established with several worldwide implant manufacturer leaders to run feasibility studies and clinical trials. The commercial launch of HEARTguide is planned for 2024 and intends to be clinically validated for four different applications. HEARTguide will be marketed in EU, US, China and Japan following market approvals by the respective competent authorities. Our business model is to include HEARTguide in the implant package sold by implant manufacturers to hospitals. According to our estimations, the company will grow to 125 employees by 2024 while generating a positive EBITDA of €10M.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEARTGUIDE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEARTGUIDE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

HAC (2019)

ADVANCED TREATMENT OF CONTAMINATED SOIL

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More